title: IL-2 activated killer cell activity is associated with the early phase of allograft rejection.
authors.affiliation: Department of Medicine, SUNY Health Science Center, Brooklyn 11203.
authors.forename: S
authors.initials: S
authors.lastname: Kamholz
authors.forename: M
authors.initials: M
authors.lastname: Roslin
authors.forename: M
authors.initials: M
authors.lastname: Mondragon
authors.forename: M
authors.initials: M
authors.lastname: Coons
authors.forename: R
authors.initials: R
authors.lastname: Tranbaugh
authors.forename: A
authors.initials: A
authors.lastname: Strashun
authors.forename: D
authors.initials: D
authors.lastname: Manjoney
authors.forename: A
authors.initials: A
authors.lastname: Norin
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D004285:Dogs; D006084:Graft Rejection; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D016040:Lung Transplantation / Q000276:immunology*; D008213:Lymphocyte Activation; D014184:Transplantation, Homologous
chemical_list: D007376:Interleukin-2